Before a video consultation about Stem Cell Therapy for Lyme Disease Abroad, the treating physician should have reviewed the records you sent. They should know how Lyme disease was diagnosed, which treatments you received, what symptoms remain, and whether another condition might explain them. If essential records are missing, the call may be useful for planning, but it cannot establish that you are eligible.

The consultation should test the proposed treatment, not simply confirm your interest in it. Stem cell therapy is experimental for Lyme disease and post-treatment Lyme disease syndrome (PTLDS). It is not an established or approved treatment for either. Antibiotics remain standard care for active Lyme infection.

First, the physician should establish which Lyme-related condition you have

Lyme disease is described by its stage and manifestations, rather than a single severity score. Early localized disease may involve erythema migrans, an expanding rash. Early disseminated disease can affect more than one body system. Late disseminated disease may involve joints or the nervous system. Your physician should explain which findings support your diagnosis and which symptoms need a separate assessment.

Reports may describe Lyme arthritis (joint inflammation), Lyme neuroborreliosis (nervous-system involvement), or Lyme carditis (heart involvement). Nervous-system manifestations can include a cranial neuropathy such as facial palsy, Lyme meningitis, or radiculoneuritis, which causes pain or weakness along a nerve root. Peripheral neuropathic symptoms, such as tingling, also deserve evaluation, but do not by themselves prove active Lyme infection.

PTLDS describes persistent symptoms following recommended treatment for Lyme disease. It does not automatically mean bacteria remain active. Persistent fatigue, pain, or difficulty concentrating may require assessment for other treatable conditions. If you have new joint swelling, facial weakness, heart symptoms, or neurological changes, the physician should address those findings rather than placing everything under a broad “chronic Lyme” label.

Imaging can help assess an affected joint or another suspected cause of symptoms, but a scan cannot establish that stem cells will help Lyme disease. The remote reviewer should distinguish what your tests show from what the clinic is assuming.

Ask back: “Which findings establish my diagnosis, and which symptoms remain unexplained?” A clear answer identifies the evidence, describes uncertainty, and says what further evaluation is needed.

Next, the physician should check whether you are suitable for any proposed cell procedure

A remote assessment starts with your records and health history. The physician should ask about antibiotic courses and response, current symptoms, other diagnoses, medications, allergies, previous procedures, and any history of cancer, immune suppression, or serious infection. They should also ask what you hope treatment will change and how that improvement could be measured.

Age alone does not decide eligibility. Diabetes, smoking, and a high body mass index can affect infection risk, healing, anesthesia decisions, or the safety of collecting cells. Older adults may have additional heart, kidney, or mobility concerns. These factors call for individual assessment, not an automatic promise or rejection.

A patient with suspected active Lyme infection needs guideline-based evaluation and treatment, not cell therapy in place of antibiotics. Unexplained fever, a possible active infection, significant heart symptoms, or rapidly changing neurological signs require prompt medical assessment. A responsible clinic should also be willing to decline treatment when the likely risks outweigh an unproven benefit.

Sending records produces a preliminary remote opinion, not final medical clearance. An in-person examination and any necessary tests must confirm whether the proposed procedure remains appropriate after you arrive.

Ask back: “What in my history could make this unsafe or change your plan?” A clear answer names your individual risk factors, the missing information, and the findings that would lead the clinic to cancel treatment.

Then, the physician should explain what may help without experimental stem cells

The alternatives depend on the diagnosis. For active Lyme disease, that means appropriate antibiotic treatment and assessment of complications. Particular manifestations, including arthritis, carditis, or neurological disease, may need specialist care. For symptoms that persist after treatment, a clinician can investigate other causes and build a plan around the problems you actually have, such as pain, sleep disturbance, reduced function, or joint limitations.

Use the comparison below to keep a proposed procedure in its clinical context.

Having a procedure at home may simplify follow-up and urgent care. Going abroad may expose you to a different proposed technique, regulatory framework, or level of clinical oversight. Neither location makes an unproven Lyme treatment effective. Compare access and continuity of care as closely as you compare the procedure itself.

Ask back: “What established options have I not tried, and why would you recommend an experimental procedure instead?” A clear answer discusses reasonable alternatives without claiming that standard Lyme care cannot help anyone with persistent symptoms.

If cell therapy is still proposed, the physician should describe exactly what would happen

“Stem cell therapy” does not identify one standardized Lyme procedure. Clinics may propose cells taken from your own bone marrow or fat, or products sourced from another person’s donated tissue. They may suggest an infusion or an injection into a particular area. Those choices are not interchangeable, and none has established effectiveness for treating Lyme disease or PTLDS.

Ask the provider to walk through the actual plan, not a general account of how stem cells might work.

1. Confirm the diagnosis and consent. The team examines you, reviews missing tests, explains the experimental nature of treatment, and confirms whether to proceed.
2. Identify the cell source. If cells are collected from you, the plan should describe the collection procedure and its risks. If they come from a donor, the plan should describe sourcing and screening.
3. Prepare and verify the product. The team should document what is processed, tested, stored, and administered. Ask which steps occur in a laboratory and under which controls.
4. Administer and observe. The physician should specify the route, who performs it, whether imaging guidance or anesthesia is used, and how you are monitored afterward.
5. Document the outcome plan. Before discharge, the team should record what will be measured, when it will be checked, and whom you contact about a problem.

Product names, cell-processing methods, and any associated materials can differ between providers and regulatory systems. Get the exact product or preparation name, manufacturer or processing facility, cell source, route of administration, and available batch or tracking information in writing. Ask whether the proposed product and its use for Lyme disease are authorized by the relevant regulator, offered within an appropriately overseen clinical trial, or offered outside either pathway. Do not assume a product used for another condition is approved for yours.

The risk discussion should cover both the procedure and the trip home

Risks vary with the cell source and administration route. Collection can cause pain, bleeding, or infection. Injections and infusions can cause local injury, infection, or a reaction to the administered product. Other concerns with poorly characterized products include contamination, unexpected tissue growth, and serious complications. The physician should explain which risks apply to the specific plan rather than relying on a generic consent form.

There is no reliable Lyme-specific complication-rate range that can be applied across these different experimental products and techniques. A clinic’s small case series or unexplained “success rate” cannot fill that gap. Ask for the provider’s documented adverse-event records and how events were identified and followed after patients returned home.

Across borders, response time matters. Before paying a deposit, establish who answers urgent questions, what the overseas team can assess remotely, and which problems require a local emergency department. Ask whether the facility can manage an immediate reaction or infection and how records would reach your doctor at home. A complication may need local treatment, while a procedure-related revision might require another trip. The responsibility and likely costs of each should be clear.

Ask back: “Which serious complications have occurred with this exact procedure, and who manages one after I leave?” A clear answer gives a route-specific emergency plan and does not describe the treatment as risk-free.

Expected results should be discussed without a Lyme “cure” promise

No dependable success range or duration of benefit has been established for stem cell therapy in Lyme disease or PTLDS. Symptom changes can occur for many reasons, including recovery over time, concurrent care, and variation in symptoms. A responsible physician should not promise that cells will eliminate infection, reverse every neurological symptom, or prevent future problems.

Instead, agree on specific measures before treatment, such as a documented joint examination, a functional activity, or a symptom score. Discuss how results will be checked and what happens if nothing improves. Repeat cell treatment should not be presented as routine maintenance when the first procedure has no established benefit for this condition. Long-term care may be better directed by your infectious-disease specialist, neurologist, or another local clinician.

Ask back: “What improvement is realistic for my particular diagnosis, and what evidence supports that expectation?” A clear answer separates published evidence from the clinic’s own observations and states plainly that benefit may be absent.

Before booking, the physician should turn the proposal into a written plan

Most medical preparation happens at home. Arrange review of unresolved symptoms with your usual doctor, send the requested records, and ask whether additional heart, neurological, joint, or infection assessment is needed. Share your full medication list. Only your treating doctors should decide whether any medication needs changing. Do not interrupt indicated Lyme treatment to qualify for a cell procedure.

A useful overseas proposal identifies the treating provider, your working diagnosis, the precise product and procedure, the reason it is being considered, major risks, expected recovery, and follow-up responsibilities. Verify the physician’s relevant license and training, the facility’s authorization for the proposed activity, product handling and testing arrangements, and access to emergency care. Ask whether an independent ethics review or trial oversight applies, if the clinic claims the treatment is part of research.

Compare plans on those clinical details before comparing quoted totals. Ask whether consultations, tests, product preparation, physician fees, anesthesia, facility charges, medicines, complication care, rehabilitation, and follow-up are included. Confirm which travel-related services, if any, are separate. Obtain the final inclusions and exclusions in writing. Treatment price and total travel cost are different, and the cheapest offer is not necessarily the safest or most appropriate.

International prices and suitable destinations cannot be responsibly reduced to one figure or a generic shortlist for an experimental, non-standardized Lyme procedure. A PlacidWay patient coordinator can help with destination comparisons, price information, and travel logistics.

A quote should also explain what happens if the in-person examination changes the plan or treatment is cancelled. Vague product descriptions, guaranteed cures, unsupported success claims, and an unclear final price are reasons to pause before paying a deposit.

Ask back: “What could change after you examine me, and what would I still owe if we do not proceed?” A clear answer sets out medical stop points and the financial terms in writing.

Finally, the physician should plan recovery with your doctor at home

There is no single recovery schedule for all cell procedures. Immediately afterward, the treating team may monitor you for a reaction and check any collection or injection site. Over the following period, they may look for pain, bleeding, or infection and assess your mobility. Later symptom review and longer-term assessment will often happen back home. The route used, anesthesia, your health, and any complication determine how much observation near the clinic is appropriate and when travel is medically reasonable.

Before departure, ask for a discharge summary, procedure report, product identification and tracking details, relevant test results, prescriptions, restrictions, and written follow-up instructions. The plan should state who reviews symptoms and results, who communicates with your local doctor, and how to reach the overseas team. If your mobility or ability to manage daily tasks is limited, discuss whether someone should travel with you.

Seek prompt local assessment for fever, worsening redness or drainage at a procedure site, severe or increasing pain, a concerning reaction, or new weakness. Chest pain, fainting, breathing difficulty, or new neurological symptoms warrant urgent medical care. The overseas clinic can review records and advise remotely, but it cannot replace an in-person examination or emergency treatment where you live.

Long-term maintenance means treating the condition that is actually found, not assuming repeated cell procedures are needed. Establish in advance whether your local clinicians will oversee ongoing Lyme-related care and who would evaluate any lasting procedure-related problem. If a further procedure is proposed, ask for a new diagnosis, rationale, and risk review before considering another trip.

Ask back: “What documents will my doctor receive, and who takes responsibility if symptoms worsen after I return?” A clear answer assigns each follow-up task to a named clinical team and explains when you need local care.

Discuss a Lyme stem cell proposal with a patient coordinator

If you are comparing overseas proposals, a patient coordinator can help you gather the written details needed for a more informed discussion with your doctors.

Request information

References

• Centers for Disease Control and Prevention — Lyme Disease
• Infectious Diseases Society of America — Clinical Practice Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease
• U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes
• National Health Service — Lyme Disease
• ClinicalTrials.gov — Clinical Studies Registry

This page is for general information and is not medical advice. Consult a qualified doctor about your diagnosis, treatment options, and personal risks.